Patient-derived 3D tumor models for sarcoma and metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PREMOD is a prospective, observational project that collects leftover tumor tissue and blood from patients with sarcoma or bone/lung metastases during routine medical care. Collected samples are used to build and optimize a range of ex vivo models, including tumor explants, primary cultures, spheroids, scaffold-based 3D cultures, 3D bioprinted constructs, alginate capsules, and chorioallantoic membrane (CAM) assays. Models are evaluated for viability and reproducibility and used for drug testing and identification of genetic and circulating biomarkers related to progression or toxicity. No experimental treatments or extra procedures are administered as part of participation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors
* Age between 0 and 85 years
* Availability of sufficient and adequate biological material (tumor tissue and/or blood)
* Signed informed consent for biobanking (BIOTUM)
* Signed informed consent for use of tissue and blood samples in this study

Exclusion Criteria:

* Diagnosis other than sarcoma or metastases from solid tumors
* Missing signed informed consent(s)

Where it's running

• Istituto Ortopedico Rizzoli
  Bologna, Italy Recruiting

Study contacts

• Study coordinator: Toni Ibrahim, MD Oncologist
• Email: toni.ibrahim@ior.it
• Phone: +39 0516366199

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gene-based grouping of bone and soft tissue tumors

  This study tests whether tumors of bone and soft tissue can be sorted into clearer genetic groups using DNA and RNA data.

  Recruiting Karolinska Institutet · Stockholm · NCT07822204

• Fluorescent abenacianine to help surgeons find lung tumors during surgery

  This tests whether a fluorescent drug called abenacianine helps surgeons see and remove lung cancer or lung metastases during planned lung surgery in adults.

  Recruiting at 9 sites Phase 3 Vergent Bioscience, Inc. · Duarte, California and 8 other locations · NCT07499674

• QL1706 treatment for advanced bone and soft tissue sarcoma

  This will try QL1706 in adults with advanced or metastatic bone and soft tissue sarcomas to see if it controls tumor growth and is well tolerated.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06939855

• Preventing pneumothorax during lung cancer treatment

  This study is testing if using a special technique called pleural blood patch can help prevent lung collapses in patients getting treatment for lung cancer.

  Recruiting Oxford University Hospitals NHS Trust · Oxford · NCT06651658

• New drug delivery method for treating sarcoma

  This study is testing a new way to deliver cancer treatment directly to hard-to-reach sarcoma tumors using tiny particles and light to see if it works better for patients with inoperable tumors.

  Recruiting at 2 sites Istituto Ortopedico Rizzoli · Bologna, Emilia-Romagna and 1 other locations · NCT06599957

• Using gamma delta T cells with low dose radiotherapy for advanced lung cancer and bone metastases

  This study is testing whether using special immune cells along with low dose radiation can help people with advanced lung cancer and bone metastases feel better.

  Recruiting at 4 sites Phase 1 Kiromic BioPharma Inc. · Tucson, Arizona and 4 other locations · NCT06069570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.